Podcast: Innovative Clinical Trial Design Identifies Effective Drug and Its Most Efficacious Dose for Treating Early Alzheimer Disease

In this September 6, 2024 Podcast episode by SciPod Health and Medicine, it summarizes the recent paper “Lecanemab for Patients with Early Alzheimer Disease: Bayesian Analysis of a Phase 2b Dose-Finding Randomized Clinical Trial” by Dr. Donald Berry and Dr. Scott Berry.

In addition, it describes the benefit and success of adaptive clinical trial design within a Bayesian statistical approach not only within this Eisai Alzheimer trial, but many other trials.  One example it highlights in another disease area, is the AWARD-5 trial for Eli Lilly’s type 2 diabetes drug Trulicity that has made it the most successful and profitable drug ever for Eli Lilly.

See the link to the Podcast here:  https://www.scipod.global/innovative-clinical-trial-design-via-artificial-intelligence-identifies-effective-drug-and-its-most-efficacious-dose-for-treating-early-alzheimer-disease/

More Recent News